Literature DB >> 8890226

Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.

G H Lowell1, C Colleton, D Frost, R W Kaminski, M Hughes, J Hatch, C Hooper, J Estep, L Pitt, M Topper, R E Hunt, W Baker, W B Baze.   

Abstract

Staphylococcal enterotoxin B (SEB), a primary cause of food poisoning, is also a superantigen that can cause toxic shock after traumatic or surgical staphylococcal wound [correction of would] infections or viral influenza-associated staphylococcal superinfections or when aerosolized for use as a potential biologic warfare threat agent. Intranasal or intramuscular (i.m.) immunization with formalinized SEB toxoid formulated with meningococcal outer membrane protein proteosomes has previously been shown to be immunogenic and protective against lethal respiratory or parenteral SEB challenge in murine models of SEB intoxication. Here, it is demonstrated that immunization of nonhuman primates with the proteosome-SEB toxoid vaccine is safe, immunogenic, and protective against lethal aerosol challenge with 15 50% lethal doses of SEB. Monkeys (10 per group) were primed i.m. and given booster injections by either the i.m. or intratracheal route without adverse side effects. Anamnestic anti-SEB serum immunoglobulin G (IgG) responses were elicited in all monkeys, but strong IgA responses in sera and bronchial secretions were elicited both pre- and post-SEB challenge only in monkeys given booster injections intratracheally. The proteosome-SEB toxoid vaccine was efficacious by both routes in protecting 100% of monkeys against severe symptomatology and death from aerosolized-SEB intoxication. These data confirm the safety, immunogenicity, and efficacy in monkeys of parenteral and respiratory vaccination with the proteosome-SEB toxoid, thereby supporting clinical trials of this vaccine in humans. The safety and enhancement of both bronchial and systemic IgA and IgG responses by the proteosome vaccine delivered by a respiratory route are also encouraging for the development of mucosally delivered proteosome vaccines to protect against SEB and other toxic or infectious respiratory pathogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890226      PMCID: PMC174432          DOI: 10.1128/iai.64.11.4686-4693.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

Review 1.  Expanding perspectives on the toxic shock syndrome.

Authors:  J D Freedman; D J Beer
Journal:  Adv Intern Med       Date:  1991

2.  Modifications to the Henderson apparatus for studying air-borne infections. Evaluations using aerosols of Listeria monocytogenes.

Authors:  W G ROESSLER; D A KAUTTER
Journal:  J Infect Dis       Date:  1962 Jan-Feb       Impact factor: 5.226

3.  Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits.

Authors:  G Hajishengallis; S K Hollingshead; T Koga; M W Russell
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

Review 4.  New perspectives in vaccine development: mucosal immunity to infections.

Authors:  J R McGhee; H Kiyono
Journal:  Infect Agents Dis       Date:  1993-04

5.  Lethally irradiated normal strains of mice radioprotected with SCID bone marrow develop sensitivity to low doses of staphylococcal enterotoxin B.

Authors:  E Aboud-Pirak; I Lubin; M E Pirak; A Canaan; G H Lowell; Y Reisner
Journal:  Immunol Lett       Date:  1995-05       Impact factor: 3.685

6.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

7.  Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (Macaca mulatta).

Authors:  M E Mattix; R E Hunt; C L Wilhelmsen; A J Johnson; W B Baze
Journal:  Toxicol Pathol       Date:  1995 May-Jun       Impact factor: 1.902

8.  Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.

Authors:  G H Lowell; R W Kaminski; S Grate; R E Hunt; C Charney; S Zimmer; C Colleton
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

9.  Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants.

Authors:  G H Lowell; L F Smith; R C Seid; W D Zollinger
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.

Authors:  T Miethke; C Wahl; K Heeg; B Echtenacher; P H Krammer; H Wagner
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  16 in total

1.  Identification of a transcytosis epitope on staphylococcal enterotoxins.

Authors:  Jeffrey W Shupp; Marti Jett; Carol H Pontzer
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

Review 3.  Novel targeted immunotherapy approaches for staphylococcal infection.

Authors:  Michael Otto
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

4.  A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection.

Authors:  Dong-Liang Hu; Jing-Chun Cui; Katsuhiko Omoe; Hiroshi Sashinami; Yuichi Yokomizo; Kunihiro Shinagawa; Akio Nakane
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 6.  Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell Receptor.

Authors:  Gang Chen; Hatice Karauzum; Hua Long; Danielle Carranza; Frederick W Holtsberg; Katie A Howell; Laura Abaandou; Bojie Zhang; Nick Jarvik; Wei Ye; Grant C Liao; Michael L Gross; Daisy W Leung; Gaya K Amarasinghe; M Javad Aman; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2019-03-27       Impact factor: 5.469

Review 7.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

8.  Development of Antistaphylococcal Vaccines.

Authors:  Jean C. Lee
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

9.  Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model.

Authors:  B G Stiles; A R Garza; R G Ulrich; J W Boles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 10.  Antibodies for biodefense.

Authors:  Jeffrey W Froude; Bradley Stiles; Thibaut Pelat; Philippe Thullier
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.